Comparisons between patients with trimethoprim–sulfamethoxazole-susceptible and trimethoprim–sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study  by Wang, Ching-Hsun et al.
Journal of Microbiology, Immunology and Infection (2016) 49, 378e386Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEComparisons between patients with
trimethoprimesulfamethoxazole-susceptible
and trimethoprimesulfamethoxazole-
resistant Stenotrophomonas maltophilia
monomicrobial bacteremia: A 10-year
retrospective study
Ching-Hsun Wang a, Jung-Chung Lin a, Hsin-An Lin a,
Feng-Yee Chang a, Ning-Chi Wang a, Sheng-Kang Chiu a,
Te-Yu Lin a, Ya-Sung Yang a, Li-Ping Kan a, Chin-Hsuan Yang a,
Ming-Chin Chan b, Kuo-Ming Yeh a,*a Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine,
Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
b Infection Control Office of Internal Medicine, Tri-Service General Hospital,
National Defense Medical Center, Taipei, TaiwanReceived 10 April 2014; received in revised form 13 June 2014; accepted 16 June 2014
Available online 28 July 2014KEYWORDS
bacteremia;
resistance;
Stenotrophomonas
maltophilia;
trimethoprim
esulfamethoxazole* Corresponding author. Division of
Hospital, National Defense Medical Ce
E-mail address: kmyeh@ndmctsgh.
http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, Taiwan
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maltophilia to trimethoprimesulfamethoxazole (TMPeSXT) is uncertain. This study
compared the clinical characteristics and outcomes of patients with TMPeSXT-susceptible
(TSSSM) and TMPeSXT-resistant S. maltophilia (TSRSM) monomicrobial bacteremia.
Methods: The medical records of adult patients with TSSSM and TSRSM monomicrobial
bacteremia from January 2004 to December 2013 were reviewed and classified into two
groups, namely, TSSSM and TSRSM.
Results: There were 184 patients with monomicrobial S. maltophilia bacteremia. The mean
age was 68.3 years. Most patients were males (72.8%), had high Charlson Comorbidity IndexInfectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General
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TMPeSXT-resistant S. maltophilia bacteremia 379scores, previously prescribed antimicrobial agents, and indwelling medical devices. The 14-
day and in-hospital mortality rates were 23.9% and 47.2%, respectively. There were 128 pa-
tients (69.6%) with TSSSM and 56 (30.4%) with TSRSM. The incidence of TSSSM bacteremia
increased during the study period. The TSSSM and TSRSM groups had similar demographic
and clinical characteristics and no significant differences in 14-day and in-hospital mortality
(24.2% vs. 23.2%, pZ 0.833; 50.0% vs. 41.1%, pZ 0.264, respectively). Patients with TSSSM
bacteremia had an increased risk of septic shock (p Z 0.044) and neutropenia (p Z 0.028)
at bacteremia onset. Logistic regression analysis indicated that acquisition of TMPeSXT
resistance was an independent risk factor for prolonged hospitalization (p Z 0.018) and
catheter-related S. maltophilia bacteremia was inversely associated with prolonged hospi-
talization after bacteremia (p Z 0.032).
Conclusion: There were no significant differences in mortality for patients with TSSSM and
TSRSM bacteremia, but patients with TSRSM bacteremia were associated with prolonged
hospitalization after bacteremia onset.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Stenotrophomonas maltophilia is a nonfermenting Gram-
negative bacillus that has emerged as an important noso-
comial pathogen primarily affecting immunocompromised
patients.1 Infection with this pathogen can manifest as
pneumonia, bloodstream infection, wound infection, or
urinary tract infection.1 Treatment of these infections is
difficult because S. maltophilia is intrinsically resistant to a
variety of structurally unrelated antimicrobial agents,
including b-lactams, cephalosporins, carbapenems, quino-
lones, and aminoglycosides although ticarcillineclavulanic
acid combination, some cephalosporins (ceftazidime,
cefoperazone, and cefepime), and new fluoroquinolones
seem to show effective in vitro activity against S. malto-
philia.2 Antibiotic resistance is mainly due to the presence
of b-lactamases, efflux pump systems, enzymatic modifi-
cation, outer membrane changes, and target site
modification.3
Trimethoprimesulfamethoxazole (TMPeSXT) is the
drug of choice for susceptible S. maltophilia infections
based on in vitro activity and anecdotal reports of
favorable clinical outcomes.2,4,5 However, recent antimi-
crobial susceptibility studies have reported the emer-
gence of TMPeSXT-resistant S. maltophilia (TSRSM), in
which resistance is mediated by acquisition of class 1
integrons and insertion element common region linked to
the sul2 genes.6e8 TSRSM species have been reported in
Taiwan since 2000.9 Infection by TSRSM species poses a
major dilemma for the clinician because of the limited
treatment options available, none of which have been
validated clinically.2,10,11
Patients with S. maltophilia bacteremia often have
polymicrobial infections and 20e40% of such infections
are catheter related.1 The bacteria most commonly
recovered concomitantly with S. maltophilia are
coagulase-negative staphylococci and enterococci.12,13
Few studies on S. maltophilia bacteremia have excluded
cases with polymicrobial bacteremia in order to eliminate
confounding effects from other bacteria.14,15 There havebeen no comparisons of patients with S. maltophilia
bacteremia due to TSRSM and TMPeSXT-susceptible S.
maltophilia (TSSSM).
We conducted a 10-year retrospective cohort study on
the clinical characteristics and outcomes of patients with
TSSSM and TSRSM monomicrobial bacteremia in our
institute.
Methods
Study design and data collection
This study was conducted at the Tri-Service General Hos-
pital, National Defense Medical Center, a 1700-bed a ter-
tiary referral center in northern Taiwan. This 10-year
retrospective cohort study examined patients who were
hospitalized from January 1, 2004, to December 31, 2013.
Medical charts were reviewed after obtaining the approval
of the Institutional Review Board of the hospital (TSGHIRB
approval number: 2-101-05-074). All patients with mono-
microbial S. maltophilia bacteremia and with clinical
symptoms or signs of infection were included for further
analysis. Patients who had polymicrobial bacteremia or
who were aged <18 years were excluded. If a patient had
multiple episodes of bacteremia, only data from the first
episode were included.
Definitions
S. maltophilia bacteremia was defined by the presence of a
blood culture that yielded S. maltophilia from one or more
collected blood samples. Hospital-acquired bacteremia was
defined by a positive blood culture obtained from patients
hospitalized for >48 hours after admission. Healthcare-
associated bacteremia was defined by a positive blood
culture obtained from patients within 48 hours of admission
and fulfilled any of the standard criteria (e.g., residence in
a nursing home).16 Community-acquired bacteremia was
defined by a positive blood culture obtained within the 48
380 C.-H. Wang et al.hours after admission for patients who did not fit the
criteria for a healthcare-associated infection.
The severity of illness was assessed by the Acute Phys-
iology and Chronic Health Evaluation II (APACHE II) score.
The Charlson Comorbidity Index (CCI) was used as an
aggregate measure for comorbidities.17 Septic shock was
defined by the presence of a systolic blood pressure
<90 mmHg or <30 mmHg below the baseline value, or
when inotropic agents were required to maintain blood
pressure with evidence of organ hypoperfusion at bacter-
emia onset. Use of antimicrobial agents prior to the
bacteremia after admission was recorded. The source of
bacteremia was determined according to the Centers for
Disease Control and Prevention definitions.18 The duration
of hospitalization after bacteremia onset was defined as
the time between the date of discharge and the date of the
first positive blood culture. A prolonged hospitalization
after bacteremia was defined as hospitalization of at least
28 days after bacteremia onset. Appropriate empiric ther-
apy was defined as microorganism susceptibility to one of
several antimicrobial agents administered within 72 hours
after the onset of bacteremia.
Microbiology
The VITEK 2 automatic system for Gram-negative rods (bio-
Me´rieux Inc., Marcy-l’E´toile, France) was used to identify
blood isolates of S. maltophilia. Susceptibility to TMPeSXT
was measured according to the updated Clinical and Labo-
ratory Standards Institute (CLSI) 2004 guideline for S. mal-
tophilia.19 When a TSRSM isolate was identified, its
susceptibility to antimicrobial agents, including ceftazidime
and ciprofloxacin, was tested with the disk diffusion method
and interpreted according to the CLSI 2004 guideline19 and
previous study results.20,21 In addition, the TSSSM isolates
were tested with both agents upon a physician’s request.
Statistical analysis
All results were analyzed using a commercially available
software package (SPSS, version 16.0; SPSS Inc., Chicago, IL,
USA). Categorical variables were analyzed using the Chi-
square test or Fisher’s exact test as appropriate. Continuous
variables were compared using Student’s t test. All p values
were two tailed and a p < 0.05 was considered statistically
significant. The effect estimates are reported as odds ratios
(ORs) and 95% confidence intervals (CIs). Variables with
p < 0.05 in the univariate logistic regression were incorpo-
rated into amultivariate logistic regressionmodel to identify
independent predictors of prolonged hospitalization. In the
final multivariable models, a p < 0.05 was considered sig-
nificant. The CochraneArmitage trend test was used to
determine whether there were increasing trends in the
incidence of TSSSM and TSRSM bacteremia during the study
period (calculated as number of TSSSM and TSRSM bacter-
emia per 100,000 discharges per year).
Results
There were 277 patients with S. maltophilia bacteremia at
our institution in the past 10 years. We excluded threepatients who were aged <18 years, 86 patients because of
evidence of polymicrobial bacteremia, and four patients
because of incomplete medical records. The study popu-
lation therefore consisted of 184 patients with S. malto-
philia monomicrobial bacteremia. Table 1 summarizes the
clinical characteristics and outcomes of these patients. The
mean age was 68.3 years and 72.8% of the patients were
male. Most bacteremic episodes (165/184, 89.7%) were
hospital acquired. The mean CCI was 4.1. A total of 149
patients (80.9%) were given at least one class of antimi-
crobial agent prior to the bacteremia, and the mean num-
ber of previous antimicrobial agents was 2.2. The main
infectious sources identified were the respiratory tract and
central venous catheters, but 45.7% of patients had
bacteremia of unknown origin.
Table 2 summarizes the clinical outcomes of the enrolled
patients. The 14-day mortality and in-hospital mortality
rates were 23.9% and 47.2%, respectively. The mean dura-
tion of hospitalization was 27.4 days after bacteremia
onset. Nearly half of the patients (45.1%) had prolonged
hospitalizations (>28 days) after bacteremia onset.
Among 184 patients with S. maltophilia monomicrobial
bacteremia, 128 (69.6%) were caused by TSSSM and 56
(30.4%) were caused by TSRSM. There was a significant
trend for increasing incidence of S. maltophilia bacteremia
(CochraneArmitage test for trend, p < 0.001) during the
study period. An analysis of the incidence of TSSSM and
TSRSM bacteremia indicated an increasing incidence of
TSSSM bacteremia (CochraneArmitage test for trend,
p < 0.001) but not TSRSM bacteremia (CochraneArmitage
test for trend, p Z 0.324, Fig. 1).
The TSRSMand TSSSM groups had similar demographic and
clinical characteristics (Table 1). There was a slightly higher
rate of mechanical ventilation in the TSRSM group and
slightlymoremales in the TSSSM group, but these differences
were not significant (pZ 0.073 and pZ 0.085, respectively).
Disease severity at bacteremia onset was evaluated by the
APACHE II score and the presence of thrombocytopenia,
neutropenia, and septic shock. Patients in the TSSSM group
had a higher risk of development of septic shock (pZ 0.044)
and neutropenia (pZ 0.028; Table 1). The TSSSM and TSRSM
groups had no significant differences in 14-day mortality and
in-hospital mortality (Table 2). The duration of hospitaliza-
tion after bacteremia onset was greater in the TSRSM group,
but this was not significant (32.9 days vs. 24.9 days,
pZ 0.126). Patients in the TSRSM group were more likely to
have prolonged hospitalization (p Z 0.030). Among the 56
blood isolates of TSRSM, 16 (28.5%) were susceptible to cef-
tazidime and four isolates (7.1%) were susceptible to cipro-
floxacin. The rate of appropriate empiric antimicrobial
therapy was higher in the TSSSM group than in the TSRSM
group (15/128 vs. 0/56, pZ 0.006). Among the 15 patients
with TSSSM bacteremia who received appropriate empiric
antimicrobial therapy, four received ceftazidime and 11
received TMPeSXT. None of the TSRSM patients received
appropriate empiric antimicrobial therapy.
Finally, we determined factors that were significantly
associated with prolonged hospitalization and in-hospital
mortality by use of logistic regression analysis (Table 3). The
initial univariate analysis indicated that variables signifi-
cantly associated with prolonged hospitalization were the
presence of TSRSM, mechanical ventilation at bacteremia
Table 1 Demographic and clinical characteristics of patients with Stenotrophomonas maltophilia monomicrobial bacteremia
Variable TSSSM (n Z 128, 69.6%) TSRSM (n Z 56, 30.4%) pe All (n Z 184)
General features, n (%)
Age, y 68.1 (17.9) 68.8 (17.9) 0.796 68.3 (17.9)
No. (%) of males 98 (76.6) 36 (64.3) 0.085 134 (72.8)
Community-acquired 3 (2.3) 0 (0) 0.554 3 (1.6)
Healthcare-associated 13 (10.2) 3 (5.4) 0.398 16 (8.7)
Hospital-acquired 112 (87.5) 53 (94.6) 0.191 165 (89.7)
Previous surgery prior to the
bacteremia episode after admission
35 (27.3) 18 (32.1) 0.508 53 (28.8)
Length of hospital stay prior to bacteremiaa 25.2 (24.0) 30.6 (25.7) 0.173 26.8 (24.6)
Mechanical ventilation 76 (59.4) 41 (73.2) 0.073 117 (63.6)
Indwelling central venous cathetersb 94 (73.4) 41 (73.2) 0.975 135 (73.4)
Comorbidity, n (%)
Previous cerebral disease 29 (22.7) 11 (19.6) 0.648 40 (21.7)
Coronary artery disease 33 (25.8) 11 (19.6) 0.369 44 (23.9)
Renal insufficiencyc 43 (33.6) 13 (23.2) 0.159 56 (30.4)
Chronic obstructive pulmonary disease 17 (13.3) 8 (14.3) 0.855 25 (13.6)
Liver cirrhosis 7 (5.5) 3 (5.4) 1.000 10 (5.4)
Type 2 diabetes mellitus 37 (28.9) 17 (30.4) 0.862 54 (29.3)
Malignancy 50 (39.1) 20 (35.7) 0.667 70 (38.0)
Charlson Comorbidity Index 4.08 (2.26) 4.3 (3.05) 0.634 4.1 (2.5)
Prior antimicrobial agent use, n (%)
Antipseudomonal penicillin-lactamase inhibitor 42 (32.8) 23 (41.1) 0.281 65 (35.3)
3rd-generation cephalosporin 41 (32.0) 21 (37.5) 0.470 62 (33.6)
4th-generation of cephalosporin 41 (32.0) 20 (35.7) 0.625 61 (33.1)
Carbapenem 61 (47.7) 25 (44.6) 0.706 86 (46.7)
Glycopeptide 49 (38.3) 20 (35.7) 0.741 69 (37.5)
Fluoroquinolone 36 (28.1) 17 (30.4) 0.758 53 (28.8)
Trimethoprimesulfamethoxazole 8 (6.2) 6 (10.7) 0.365 14 (7.6)
No. of antibiotics used prior to bacteremiaa 2.2 (1.6) 2.4 (1.6) 0.479 2.2 (1.6)
Clinical condition at bacteremia onset, n (%)c
Thrombocytopeniac 47 (36.7) 21 (37.5) 0.920 68 (37.0)
APACHE II score 21.6 (9.8) 21.9 (7.3) 0.859 21.7 (9.1)
Neutropeniac 15 (11.7) 1 (1.8) 0.028 16 (8.7)
Septic shock 33 (25.8) 7 (12.5) 0.044 40 (21.7)
Primary source of bacteremia
Respiratory tract 49 (38.3) 23 (41.1) 0.721 72 (39.1)
Central venous catheter-related 14 (10.9) 8 (14.3) 0.520 22 (12.0)
Unknown origin 59 (46.1) 25 (44.6) 0.856 84 (45.7)
Othersd 6 (4.7) 1 (1.8) 0.677 7 (3.8)
a Data are presented as mean (standard deviation).
b Double-lumen catheter for hemodialysis, central venous catheters, peripherally inserted central catheter included.
c Thrombocytopenia was diagnosed by a platelet count <100,000/mL, neutropenia by an absolute neutrophil count <1500/mL, and
renal insufficiency by a serum creatinine level >2 mg/dL.
d Five cases had abdominal origin, two cases were from wounds.
e For comparison of the TMPeSXT-susceptible S. maltophilia and TMPeSXT-resistant S. maltophilia groups.
APACHE II Z Acute Physiologic and Chronic Health Evaluation II score; TMPeSXT Z trimethoprimesulfamethoxazole;
TSRSM Z TMPeSXT-resistant S. maltophilia; TSSSM Z TMPeSXT-susceptible S. maltophilia.
TMPeSXT-resistant S. maltophilia bacteremia 381onset, septic shock at bacteremia onset, thrombocytopenia,
and APACHE II score but catheter-related infection was
inversely associatedwith prolonged hospitalization (p< 0.05
for all, Table 3). The results of multivariate analysis indi-
cated that prolonged hospitalization was independently
associated with the presence of TSRSM (OR Z 2.349,
pZ 0.018) and inversely associated with catheter-related S.
maltophilia bacteremia (ORZ 0.285, pZ 0.032).The initial univariate analysis indicated that mechanical
ventilation, septic shock, thrombocytopenia, APACHE II
score, and neutropenia at bacteremia onset and S. malto-
philia bacteremia resulting from respiratory tract in-
fections were significantly associated with in-hospital
mortality (p < 0.05 for all, Table 3). The results of multi-
variate analysis indicated that only the APACHE II score and
thrombocytopenia were independently associated with in-
Table 2 Antimicrobial therapy and clinical outcomes of patients with Stenotrophomonas maltophilia monomicrobial
bacteremia
Variable TSSSM (n Z 128) TSRSM (n Z 56) pb All (n Z 184)
Antimicrobial therapy, n (%)
Appropriate empiric antimicrobial therapy 15 (11.7) 0 (0) 0.006 15 (8.1)
Clinical outcome, n (%)
14-d mortality 31 (24.2) 13 (23.2) 0.833 44 (23.9)
In-hospital mortality 64 (50.0) 23 (41.1) 0.264 87 (47.2)
Duration of hospitalization after bacteremia onseta 24.9 (23.2) 32.9 (35.3) 0.126 27.4 (27.6)
Prolonged hospital stay (28 d after bacteremia) 51 (39.8) 32 (57.1) 0.030 83 (45.1)
a Data are presented as mean (standard deviation).
b For comparison of the TMPeSXT-susceptible S. maltophilia and TMPeSXT-resistant S. maltophilia groups.
TMPeSXT Z trimethoprimesulfamethoxazole; TSRSM Z TMPeSXT-resistant S. maltophilia; TSSSM Z TMPeSXT-susceptible S.
maltophilia.
382 C.-H. Wang et al.hospital mortality (OR Z 1.151 and OR Z 4.430, and
p < 0.001, respectively, Table 3).
Discussion
This 10-year retrospective cohort study analyzed the re-
cords of 184 patients with S. maltophilia monomicrobial
bacteremia. To our knowledge, this is the largest retro-
spective observational study of S. maltophilia bacteremia.
We compared cases with TSRSM and TSSSM bacteremia after
exclusion of patients with polymicrobial bacteremia, and
such a comparison has not been made in any other studies
to date. In our study, the incidence of TSSSM bacteremia
increased during the 10-year study period. Although there
was no difference in 14-day mortality and in-hospital102 43
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Figure 1. Incidence of TSSSM and TSRSM monomicrobial
bacteremia from 2004 to 2013 at the Tri-Service General
Hospital, National Defense Medical Center (Taipei, Taiwan).
For each year from 2004 to 2013, there were 7, 12, 10, 10, 10,
8, 10, 16, 27, and 18 patients with TSSSM bacteremia, and 5, 2,
10, 9, 1, 3, 5, 3, 6, and 12 patients with TSRSM bacteremia. For
each year from 2004 to 2013, there were 49,260, 46,620,
46,876, 47,363, 44,961, 48,189, 49,454, 50,502, 48,362, and
48,115 discharged patients. The CochraneArmitage Trend test
indicated a significant increase in TSSSM bacteremia
(p < 0.001), but not in TSRSM bacteremia (p Z 0.324).
TMPeSXT Z trimethoprimesulfamethoxazole; TSRSM
Z TMPeSXT-resistant S. maltophilia; TSRSM Z TMPeSXT-sus-
ceptible S. maltophilia.mortality in the TSSSM and TSRSM groups, patients with
TSRSM bacteremia were associated with prolonged hospi-
talization than the TSSSM group after bacteremia onset.
The results of this study indicated that patients with S.
maltophilia bacteremia tended to have prolonged hospi-
talization prior to bacteremia onset, previous use of anti-
microbial agents, use of an indwelling medical device, and
compromised health status (high CCI), which are in agree-
ment with the results of previous studies.1,22,23 Of note,
most of our included cases had healthcare-associated and
hospital-acquired bacteremia, suggesting that exposure to
extensive healthcare system was a major risk factor for S.
maltophilia bacteremia. Although our prevalence of hos-
pital-acquired S. maltophilia bacteremia was higher than
that in a tertiary hospital in southern Taiwan [165/184
(89.7%) vs. 94/153 (61.4%), respectively],24 it was similar to
those in two hospitals in northern Taiwan [64/84 (76%) and
46/50 (92%), respectively].25,26
The primary sources of S. maltophilia bacteremia were
the respiratory tract and intravascular catheters, possibly
because a high percentage of the included patients were
ventilator dependent and had indwelling intravascular
catheters. Patients with TSRSM and TSSSM bacteremia had
comparable general demographic and clinical characteris-
tics, comorbidities, sources of bacteremia, and previous
use of antimicrobial agents. We observed that TSRSM
bacteremia had a trend toward occurring in ventilator-
dependent patients. This is consistent with a previous study
claiming that patients requiring prolonged mechanical
ventilation tend to become reservoirs of antimicrobial
resistance.27 The relation with environment factor (e.g.,
intensive care unit, respiratory care center (RCC)) should
be considered in this association.
The APACHE II scores and incidence of thrombocytopenia
at bacteremia onset were similar in the TSRSM and TSSSM
groups. However, the rates of septic shock and neutropenia
were higher in the TSSSM group than in the TSRSM group,
suggesting that TSSSM is more virulent than TSRSM. Resis-
tance acquisition in many microorganisms associated with
virulence changes linked to clinical infectious diseases had
been reported previously.28 In some cases, the increased
antimicrobial resistance is associated with reduced viru-
lence, such as the acquisition of b-lactamases in Escher-
ichia coli and the acquisition of vancomycin resistance in
methicillin-resistant Staphylococcus aureus.29,30 This may
Table 3 Logistic regression analysis of factors associated with in-hospital mortality and prolonged hospitalization (28 d after bacteremia onset) in patients with Steno-
trophomonas maltophilia monomicrobial bacteremia
Variable In-hospital mortality Prolonged hospitalization
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Odds ratio (95% CI) p Odds ratio (95% CI) p Odds ratio (95% CI) p Odds ratio (95% CI) p
Age, y 1.013 (0.996e1.030) 0.134 1.004 (0.987e1.020) 0.661
TSRSM 0.697 (0.369e1.315) 0.265 2.013 (1.065e3.805) 0.031 2.349 (1.161e4.753) 0.018
Previous surgery 0.646 (0.338e1.236) 0.187 1.010 (0.532e1.917) 0.976
Mechanical ventilation 8.185 (3.945e16.981) <0.001 2.302 (0.824e6.430) 0.112 3.403 (1.773e6.530) <0.001 1.508 (0.674e3.373) 0.317
Clinical condition
Septic shock 5.413 (2.398e12.219) <0.001 2.146 (0.742e6.204) 0.159 2.835 (1.365e5.885) 0.005 1.805 (0.778e4.187) 0.169
Neutropenia 3.720 (1.153e12.007) 0.028 4.345 (0.784e24.072) 0.093 2.933 (0.976e8.816) 0.055
Thrombocytopenia 8.522 (4.237e17.141) <0.001 4.430 (1.906e10.300) 0.001 2.201 (1.196e4.409) 0.011 1.462 (0.719e2.975) 0.295
APACHE II score
(per 1-point increment)
1.204 (1.137e1.274) <0.001 1.151 (1.074e1.233) <0.001 1.078 (1.039e1.119) <0.001 1.048 (0.999e1.099) 0.053
Comorbidity
Charlson Comorbidity Index 1.016 (0.906e1.140) 0.780 0.988 (0.880e1.108) 0.831
Source of bacteremia
Respiratory tract 2.292 (1.252e4.195) 0.007 1.496 (0.667e3.352) 0.328 1.261 (0.696e2.286) 0.444
Central venous catheter-related 0.478 (0.185e1.235) 0.128 0.317 (0.112e0.899) 0.031 0.285 (0.090e0.899) 0.032
Unknown origin 0.659 (0.367e1.183) 0.163 1.439 (0.802e2.582) 0.222
Antimicrobial therapy
Appropriate empiric
antimicrobial therapy
1.302 (0.452e3.752) 0.625 0.414 (0.127e1.353) 0.144
APACHE II Z Acute Physiologic and Chronic Health Evaluation II score; CI Z confidence interval; TMPeSXT Z trimethoprimesulfamethoxazole; TSRSM Z TMPeSXT-resistant S.
maltophilia.
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384 C.-H. Wang et al.possibly explain the different clinical presentations of pa-
tients in the two groups in our study, although we did not
specifically examine the relationship between changes in
virulence and acquisition of resistance in S. maltophilia.
Previous studies reported that the crude mortality
associated with S. maltophilia bacteremia ranged from 23%
to 69%, depending on the study population.15,31 In our
study, the 14-day and in-hospital mortality rates were
23.9% and 47.2%, respectively. There were no statistical
differences in 14-day and in-hospital mortality of the TSRSM
and TSSSM groups. In addition, it was also shown that the
APACHE II score and thrombocytopenia were associated
with in-hospital mortality. Previous studies showed that
TSRSM infection was associated with serious morbidity
rather than in-hospital mortality in debilitated patients,
and that organ dysfunction was significantly associated with
mortality in TSRSM infections.32,33 Our study strengthened
the previous conclusions that TSRSM infection was not
associated with increased mortality, even in patients with
bloodstream infections.
Patients with TSRSM bacteremia had a higher rate of
prolonged hospitalization after bacteremia onset than
those with TSSSM bacteremia. Further analysis of risk fac-
tors associated with prolonged hospitalization indicated
that TSRSM bacteremia was the only factor significantly
associated with prolonged hospitalization. We anticipated
that prolonged hospitalization would be associated with
increased morbidity and possibly higher costs of care
although we did not analyze hospital costs in this study.
Previous studies regarding the impact of other multiple
drug-resistant Gram-negative bacterial infections indicated
that multidrug resistance was associated with longer hos-
pitalization and greater mortality.34e37 Our study results
are in agreement with existing evidence that infections
caused by multidrug-resistant bacteria are associated with
increased financial burdens in healthcare systems.
Our study also showed that catheter-related S. malto-
philia bacteremia was inversely associated with prolonged
hospitalization (OR Z 0.285, p Z 0.032). This finding is
consistent with previous studies, which reported that
catheter-related S. maltophilia bacteremia was associated
with reduced mortality, possibly because most such cases
are less complicated and respond well following removal of
the infected catheter.26,38,39 Thus, our results support the
need for careful evaluation of indwelling catheters in pa-
tients who present with S. maltophilia bacteremia, and
that early removal of infected catheters is crucial to
improve the outcomes of such patients.
Among patients with S. maltophilia infections, the
prevalence of TSRSM is 2% in medical centers in Latin
America, 10% in Europe, and 8% in the Asia-Pacific region.7
A previous study of antimicrobial resistance in blood iso-
lates of S. maltophilia in Taiwan from 1998 to 2008 showed
that 85.4% of isolates were susceptible to TMPeSXT.40
Recent studies, however, reported that the TMPeSXT sus-
ceptibility of S. maltophilia in southern Taiwan was only
68.9%.24 In agreement with these most recent results, we
found that 69.6% of our isolates were susceptible to
TMPeSXT. Based on recent antimicrobial susceptibility re-
sults of blood isolates of S. maltophilia and the results re-
ported here,24 we suggest that clinicians in Taiwan should
use TMPeSXT as empirical therapy with caution for patientswhen S. maltophilia infections were suspected, because of
high frequency of TMPeSXT resistance. Continued surveil-
lance and additional research should focus on potentially
effective alternatives to TMPeSXT for the treatment of S.
maltophilia infections. Recent studies had shown that
TMPeSXT in combination with other antimicrobial agents as
ceftazidime or ciprofloxacin was more active than treat-
ment with TMPeSXT alone.41 Although clinical benefit of
such combination therapy has not been validated, it may be
considered a therapeutic option to TSRSM infection.33
Suitable methods of S. maltophilia susceptibility testing
evolved significantly over the past decade. In the CLSI 2004
guideline, S. maltophilia and Pseudomonas aeruginosa
shared the same interpretive criteria of zone diameter and
minimum inhibitory concentration (MIC) of antibiotics
including TMPeSXT, ceftazidime, and ciprofloxacin.19
Although TMPeSXT is shown to exhibit good correlation be-
tween both tests,42 broth microdilution test, instead of disk
diffusion method, is preferred for determining susceptibility
against ciprofloxacin and ceftazidime on S. maltophilia.43,44
Therefore, the CLSI 2014 guideline recommended only MIC
for ceftazidime, disk diffusion, and/or broth microdilution
for TMPeSXT, and no more test for ciprofloxacin.45
There are a few limitations in this study. This investigation
was a retrospective design, and so theremay have been some
selection and observational bias. In addition, not all of the
isolates were available. Other potentially active agents with
in vitro effects against S. maltophilia, such as levofloxacin,
ticarcillineclavulanic acid, minocycline, and chloramphen-
icol, were not tested in our hospital and estimates of their
clinical effects are unavailable. Finally, we used standards
for antimicrobial susceptibility testing of ceftazidime and
ciprofloxacin according to the CLSI 2004 guideline, not ac-
cording to the CLSI 2014 guideline.
In conclusion, patients with TSSSM monomicrobial
bacteremia were more likely to develop septic shock and
neutropenia at bacteremia onset than those with TSRSM
monomicrobial bacteremia. Although there were no sig-
nificant differences in 14-day and in-hospital mortality
rates, patients with TSRSM were more likely to have pro-
longed hospitalization than those with TSSSM.
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